This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Cervical Cancer or Cervical Precancerous Lesions
and you are
between 10 and 18
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The primary study hypothesis is that a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent HPV infection and cervical neoplasia caused by HPV types included in the vaccine.

Provided treatments

  • Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
Tris trial is registered with FDA with number: NCT00923702. The sponsor of the trial is Dr R. Sankaranarayanan and it is looking for 20000 volunteers for the current phase.
Official trial title:
Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India